Bolt Biotherapeutics (BOLT) stock price, revenue, and financials

Bolt Biotherapeutics market cap is $60.8 m, and annual revenue was $215 k in FY 2019

$60.8 M

BOLT Mkt cap, 23-May-2022
Bolt Biotherapeutics Net income (Q1, 2021)-24.5 M
Bolt Biotherapeutics EBIT (Q1, 2021)-18.4 M
Bolt Biotherapeutics Cash, 31-Mar-202195.5 M
Bolt Biotherapeutics EV-24 M
Get notified regarding key financial metrics and revenue changes at Bolt BiotherapeuticsLearn more
Banner background

Bolt Biotherapeutics Income Statement

Annual

USDFY, 2018FY, 2019

Revenue

215.0k

R&D expense

9.4m26.0m

General and administrative expense

2.2m5.2m

Operating expense total

11.6m31.2m

EBIT

(11.6m)(31.0m)

EBIT margin, %

(14404%)

Interest income

193.0k524.0k

Net Income

(11.6m)(30.5m)

EPS

(7.0)(15.3)

Quarterly

USDQ1, 2021

R&D expense

14.1m

General and administrative expense

4.3m

Operating expense total

18.4m

EBIT

(18.4m)

Investment income

56.0k

Net Income

(24.5m)

Bolt Biotherapeutics Balance Sheet

Annual

USDFY, 2018FY, 2019

Cash

13.6m34.8m

Prepaid Expenses

466.0k1.1m

Current Assets

14.1m35.9m

PP&E

1.4m1.4m

Total Assets

16.0m48.4m

Accounts Payable

892.0k2.1m

Short-term debt

40.0k3.1m

Current Liabilities

2.8m8.7m

Long-term debt

7.1m

Total Debt

40.0k10.2m

Total Liabilities

3.6m16.8m

Preferred Stock

28.4m77.5m

Additional Paid-in Capital

1.2m1.8m

Retained Earnings

(17.2m)(47.7m)

Total Equity

(15.9m)(45.8m)

Debt to Equity Ratio

0 x-0.2 x

Debt to Assets Ratio

0 x0.2 x

Financial Leverage

-1 x-1.1 x

Quarterly

USDQ3, 2020Q1, 2021

Cash

17.8m95.5m

Prepaid Expenses

1.9m4.5m

Current Assets

39.7m271.2m

PP&E

4.2m3.9m

Total Assets

61.7m324.6m

Accounts Payable

3.4m2.9m

Short-term debt

1.3m1.6m

Current Liabilities

9.9m12.0m

Long-term debt

9.7m9.1m

Total Debt

11.0m10.7m

Total Liabilities

31.0m21.4m

Common Stock

36.3m

Preferred Stock

105.3m

Additional Paid-in Capital

2.8m436.2m

Retained Earnings

(77.4m)(132.9m)

Total Equity

(74.6m)303.2m

Debt to Equity Ratio

-0.1 x

Debt to Assets Ratio

0.2 x

Financial Leverage

-0.8 x1.1 x

Bolt Biotherapeutics Cash Flow

Annual

USDFY, 2018FY, 2019

Net Income

(11.6m)(30.5m)

Depreciation and Amortization

302.0k335.0k

Accounts Payable

1.3m2.1m

Cash From Operating Activities

(9.9m)(26.3m)

Purchases of PP&E

(290.0k)(508.0k)

Cash From Investing Activities

(290.0k)(508.0k)

Long-term Borrowings

(39.0k)(40.0k)

Cash From Financing Activities

19.1m48.6m

Net Change in Cash

8.9m21.8m

Interest Paid

4.0k

Quarterly

USDQ3, 2019Q3, 2020Q1, 2021

Net Income

(21.1m)(29.7m)(24.5m)

Depreciation and Amortization

239.0k390.0k272.0k

Accounts Payable

365.0k(221.0k)(88.0k)

Cash From Operating Activities

(20.1m)(34.4m)(16.6m)

Purchases of PP&E

(441.0k)(2.4m)(58.0k)

Cash From Investing Activities

(441.0k)(22.3m)(190.5m)

Long-term Borrowings

(40.0k)

Cash From Financing Activities

48.6m40.7m297.0m

Net Change in Cash

28.1m(16.1m)89.9m

Bolt Biotherapeutics Ratios

USDFY, 2018

Financial Leverage

-1 x

Bolt Biotherapeutics Operating Metrics

FY, 2020

Co-Owned Patent Applications (Foreign)

50

Co-Owned Patent Applications (US)

21

Patents (US)

1